Engram - Edge
A cutting-edge platform to develop personalized brain organoids using patient-derived induced pluripotent stem cells (iPSCs).
At Engram Edge, we employ advanced techniques like cellular and molecular biology, gene editing, electrophysiology, and optogenetics to investigate and describe potential neurophysiological alterations in patient-derived brain organoids.
We offer comprehensive results with unprecedented temporal and spatial resolution, allowing the development of more precise and personalized treatments.
Meet the cofounders
-
Kris Blanchard
THE VISIONARY LEADER
Molecular Biotechnology Engineer with a Ph.D. in Sciences, specializing in Molecular Biology, Cellular Biology, and Neuroscience from the University of Chile, and a Ph.D. in Neurosciences from Université Sorbonne Paris Cité. As an expert in biotechnology and electrophysiology, Kris has an extensive background in neuroscience research, having completed his doctoral and postdoctoral studies in Paris.
-
Francisca Cornejo
THE SCIENTIFIC INNOVATOR
Holds a Biochemistry degree and a Ph.D. in Medical Sciences from Pontificia Universidad Católica de Chile. Her postdoctoral research on neurodevelopment at Universidad Mayor, in collaboration with the University of Dundee, involved working with genetically modified IPSCs. Additionally, she received specialized training in developing human brain organoids at Dr. Sergiu Pasca's lab at Stanford University.
-
Maximiliano Silva
THE STRATEGIC BUSINESS DEVELOPER
As the former Country Manager for Chile and Expansion Director at The Not Company, he played a pivotal role in establishing the company’s leadership in the market. From 2014 to 2018, he managed industrial operations in Peru, and between 2019 and 2024, he successfully launched 10 product categories and built a supply chain across multiple regions, including Chile, Latin America, and Oceania.
Get in touch.
We are eager to work with you.